To provide a pharmaceutical composition for treatment of multiple myeloma.
A pharmaceutical composition for treatment of multiple myeloma in a subject comprises (a) HuLuc63 which is a humanized IgG1 antibody having a heavy chain variable region corresponding to sequence number 5 and a light chain variable region corresponding to sequence number 6 and (b) dexamethasone, where any other active ingredient is not administered to the subject. And a pharmaceutical composition comprises (a) HuLuc63 which is a humanized IgG1 antibody having a heavy chain variable region corresponding to sequence number 5 and a light chain variable region corresponding to sequence number 6, (b) dexamethasone and (c) thalidomide, where any other active ingredient is not administered to the subject.
JP5340935B2 | 2013-11-13 | |||
JP5340935B2 | 2013-11-13 |
US20060024296A1 | 2006-02-02 | |||
US20060024296A1 | 2006-02-02 |
JPN6012047163; J.Clin.Oncol., 2006.1.20, Vol. 24, No. 3, P. 431-436